NCI Definition: A usually well differentiated mucinous adenocarcinoma of the peritoneum. The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the appendix. Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported. In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei. However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary. 
There are 2 clinical trials for pseudomyxoma peritonei, of which 2 are open and 0 are completed or closed. Of the trials that contain pseudomyxoma peritonei as an inclusion criterion, 2 are phase 1 (2 open).
Sgn-stnv and irinotecan sucrosofate are the most common interventions in pseudomyxoma peritonei clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.